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likely include peripheral actions on cannabinoid (CB) re-
ceptors 1 and 2 (CB 1 and CB 2 ), and may also include cen-
tral actions.
 The past 10 years have seen a constant rise in publica-
tions dealing with the anti-inflammatory effects of CBs 
and the potential underlying mechanisms. Preclinical 
data on the ameliorating effect of synthetic and natural 
CBs in animal models mimicking features of IBD have 
been rapidly evolving. The reasonable idea that CBs 
would also be beneficial in IBD patients was mainly based 
on results from experiments in CB receptor knockout 
mice and on data using CB receptor agonists and antago-
nists. Following a previous publication of a retrospective, 
observational study by Naftali et al.  [2] and a question-
naire performed by a different group in patients with ul-
cerative colitis and Crohn’s disease  [3] , both revealing 
symptom relief and improvement after use of cannabis, 
Naftali et al.  [1] have now presented a placebo-controlled 
prospective study in 21 patients with Crohn’s disease un-
responsive to standard IBD treatment. Although the pri-
mary end point of induction of remission was statistical-
ly not achieved, they were able to demonstrate that an 
8-week treatment with tetrahydrocannabinol (THC)-
rich cannabis caused a decrease in the Crohn’s disease 
activity index in 90% of patients without producing sig-
nificant side effects. The authors rightfully concluded 
that a larger patient group is warranted for future studies.
 This is the first clinical trial on the effect of cannabis in 
IBD, and it confirms what has been suggested for a long 
time from experimental studies, namely that CBs may 
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 Abstract 
 In ancient medicine, cannabis has been widely used to cure 
disturbances and inflammation of the bowel. A recent clini-
cal study now shows that the medicinal plant  Cannabis sa-
tiva has lived up to expectations and proved to be highly 
efficient in cases of inflammatory bowel diseases. In a pro-
spective placebo-controlled study, it has been shown what 
has been largely anticipated from anecdotal reports, i.e. that 
cannabis produces significant clinical benefits in patients 
with Crohn’s disease. The mechanisms involved are not yet 
clear but most likely include peripheral actions on cannabi-
noid receptors 1 and 2, and may also include central actions.
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provide anti-inflammatory effects and symptomatic ben-
efit in patients with IBD. The physiological basis for the 
beneficial effects of cannabis has been established a while 
ago and unraveled since then. The discovery of CB recep-
tors and endogenous molecules activating these receptors 
led to the description of a coordinated network that is in-
herent to the mammalian organism, the so-called endo-
cannabinoid system. This system consists of the canoni-
cal CB receptors (CB 1 , CB 2 ), their endogenous ligands 
anandamide and 2-arachidonoyl glycerol (2-AG), also 
called endocannabinoids, and their synthesizing and de-
grading enzymes. What capsaicin, the pungent ingredi-
ent of chili, is for vanilloid receptors and morphin for 
opioid receptors is THC, the psychedelic ingredient of 
cannabis, for CB receptors: the predominant herbal li-
gand. Thus, THC mimics the actions of anandamide and 
2-AG.
 The wall of the gastrointestinal tract houses all compo-
nents of the endocannabinoid system. Recent data show 
that these components are differentially expressed in hu-
man IBD indicating a regulatory role in the disease pro-
gression  [4] . While anandamide and its synthesizing en-
zyme display lower levels in ulcerative colitis, expression 
of CB 2 receptors and enzymes responsible for synthesis 
and degradation of 2-AG were increased  [5] . The findings 
indicate that the CB 2 receptor plays a key role in the ame-
liorating effect of CBs in IBD. The precise mechanism as 
to how CBs contribute to the improvement of IBD, how-
ever, is not clear but by use of experimental models of 
intestinal inflammation we are able to define a picture on 
how and at which targets CBs cause improvement of 
 inflammation.
 CB 1 and CB 2 receptors are located at the colonic epi-
thelium, and a protective effect of THC via epithelial per-
meability is conceivable ( fig. 1 ). Therefore, CBs could en-
hance epithelial wound closure in the colon  [6] . One of 
the prominent features of CBs in experimental intestinal 
inflammation is their effect on immunocytes which main-
ly express CB 2 receptors. Upon CB 2 activation, T cells un-
dergo apoptosis and decreased proliferation in colitis  [7] . 
Additionally, activation of CB 2 diminishes the recruit-
ment of neutrophils, T cells and macrophages to the in-
flamed colon  [7] . CB receptors are also found in the en-
teric nervous system (ENS), which controls gut motility 
and secretion  [8] . CB 1 receptors present in the ENS rep-
resent a break that protects the ENS from hyperstimula-
tion, a situation easily caused by overexpression of in-
flammatory mediators that activate the ENS during IBD. 
Therefore, activation of CB receptors by THC may reduce 
hypermotility associated with the inflammation of the gut 
 Fig. 1. Potential targets and mechanisms of 
CBs involved in the improvement of IBD. 
Natural and synthetic CBs act via intestinal 
CB 1 and CB 2 receptors to regulate epithe-
lial permeability, motility, secretion (via 
the enteric nervous system), as well as leu-
kocyte migration, recruitment and apopto-
sis. As the site with the highest CB 1 expres-
sion (but also some CB 2 expression), the 
brain may modulate motility, the sensation 
of pain and unpleasantness, thus positively 

































 [9] . The reduction of hypermotility may consequently 
 alleviate diarrhea producing beneficial effects for the 
 patient.
 It should be emphasized that the brain is the major site 
of CB 1 expression and that the presence of CB 2 has also 
been detected in the brainstem  [8] . The use of cannabis in 
improving inflammation could therefore well include 
central effects, such as a reduction in pain sensation and 
relief of nausea and feeling of unpleasantness. One report 
suggests that a full anti-inflammatory response of CBs in 
gut inflammation includes the central nervous system 
since a peripherally restricted CB 1 /CB 2 receptor agonist 
was either not effective or too weak to improve colitis, 
depending on the experimental model used  [10] .
 In their prospective study, Naftali et al.  [1]  used THC-
free cannabis as placebo with no other CBs present. How-
ever, we should consider that also other ingredients of 
cannabis, such as cannabidiol, cannabigerol and tetrahy-
drocannabivarine, all of them nonpsychotropic compo-
nents of cannabis, have proven anti-inflammatory effects 
in experimental intestinal inflammation  [9] . Their ac-
tions partly involve non-CB receptor mechanisms via, 
for instance, peroxisome proliferator-activated receptors 
(PPARs) and transient receptor potential cation channels 
subfamily V receptors (TRPVs) and should be regarded 
as additive beneficial effects of cannabis in the improve-
ment of colitis in addition to THC-mediated effects.
 In summary, in agreement with the ancient use of can-
nabis in intestinal disturbances and one decade of animal 
research, cannabis was shown in a clinical trial to reduce 
symptoms in patients with Crohn’s disease. This elegant 
translation should be followed by larger trials confirming 
these results and by trials establishing the involved mech-
anisms to open a promising direction for future treat-
ment of IBD.
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